Grb2+/−
|
|
[46] |
Grb2(T)−/−
|
|
[51] |
Rasgrp1−/−
|
20% reduction in thymocyte cellularity
Mild defect in β selection, but normal α-CD3ε induced proliferation in Rag2−/−
Defective positive selection
Normal negative selection
|
[16,26,27,34,38] |
Rasgrp4−/−
|
|
[38] |
Rasgrp1/Rasgrp4 DKO |
80% reduction in thymocyte cellularity
Defective βselection
Possible defect in positive selection (more than RasGRP1−/−) due to further reduction in peripheral T cell numbers
Negative selection not examined
|
[38] |
Sos1(T)−/−
|
50% reduction in thymocyte cellularity
Proliferative defect at β-selection checkpoint/defective α-CD3ε-induced proliferation in Rag2−/−
Normal positive and negative selection
|
[26,27] |
Sos2−/−
|
|
[27] |
Sos1(T)/Rasgrp1 DKO |
|
[27] |
Rasgrf2−/−
|
|
[37] |
Rasa1−/− (p120RasGAP deficient) |
Normal β-selection
Enhanced MHC class II-mediated positive selection
Normal negative selection
Reduced IL-7-mediated survival of naïve peripheral CD4+ and CD8+ lymphocytes
|
[71] |
Nras−/−
|
Normal positive and negative selection
Reduced antiviral responses
Impaired TH1 differentiation/INFγ responses
|
[72,73] |
Hras−/−
|
|
[72] |
Mapk3−/− (ERK1 deficient) |
|
[7,9] |
Mapk1−/− (ERK2 deficient) |
50% reduction in thymocyte cellularity
Defective β selection
Defective positive selection, negative selection not tested
Impaired TH1 differentiation
Impaired T cell proliferation and survival
|
[7,74,75] |
Mapk3/Mapk1 DKO (ERK1 and ERK2 deficient) |
75% reduction in thymocyte cellularity
Defective β selection
Defective positive selection
Normal negative selection
|
[7,47] |
Lat-Y136F |
Defective β selection
Defective positive and negative selection
Develop an ERK-dependent TH2 lymphoproliferative disease dependent, in part, on signaling via Bam32, RasGRP1, and Sos1/2
|
[11,12,54,55] |